State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care
American Society of Clinical Oncology Educational Book · 2024-06 · 44 (3)
DOI: 10.1200/edbk_431060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2024-06. Verfasst von Nicole Baranda Balmaceda und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Stomach Neoplasms, Precision Medicine, Biomarkers, Tumor. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 170 Literaturangaben.
Abstract (Originalsprache)
Gastroesophageal cancers (GECs) represent a significant clinical challenge. For early resectable GEC, the integration of immune checkpoint inhibitors into the perioperative chemotherapy and chemoradiation treatment paradigms are being explored and showing promising results. Frontline management of metastatic GEC is exploring the role of targeted therapies beyond PD-1 inhibitors, including anti–human epidermal growth factor receptor 2 agents, Claudin 18.2 inhibitors, and FGFR2 inhibitors, which have shown considerable efficacy in recent trials. Looking ahead, ongoing trials and emerging technologies such as bispecific antibodies, antibody-drug conjugates, and adoptive cell therapies like chimeric antigen receptor T cells are expected to define the future of GEC management. These advancements signify a paradigm shift toward personalized and immunotherapy-based approaches, offering the potential for improved outcomes and reduced toxicity for patients with GEC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
- Medical Oncology Unit, Ospedale del Mare, Naples, Italy.
- Division of Oncology and Hematology, Department of Medicine, University of Nebraska Medical Center, Omaha, NB.
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Department of Hematology-Oncology, National University Cancer Institute, Singapore.
- Department of Medicine, National University Hospital, Singapore, Singapore.
ORCID-Profile: Raghav Sundar
Zitieren
APA
Balmaceda, N. B., Petrillo, A., Krishnan, M., Zhao, J. J., Kim, S., Klute, K. A., & Sundar, R. (2024). State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society of Clinical Oncology Educational Book, 44(3). https://doi.org/10.1200/edbk_431060
Vancouver
Balmaceda NB, Petrillo A, Krishnan M, Zhao JJ, Kim S, Klute KA, et al. State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care. American Society of Clinical Oncology Educational Book. 2024;44(3). doi:10.1200/edbk_431060
BibTeX
@article{Balmaceda2024,
author = {Balmaceda, Nicole Baranda and Petrillo, Angelica and Krishnan, Mridula and Zhao, Joseph J and Kim, Sunnie and Klute, Kelsey A and Sundar, Raghav},
title = {State-of-the-Art Advancements in Gastroesophageal Cancer Treatment: Harnessing Biomarkers for Precision Care},
journal = {American Society of Clinical Oncology Educational Book},
year = {2024},
volume = {44},
number = {3},
doi = {10.1200/edbk_431060}
}
EUVIMED